Aspirin

SAN FRANCISCO — Among patients who underwent PCI with a bioresorbable polymer sirolimus-eluting stent, 3-month dual antiplatelet therapy was noninferior to longer DAPT, according to results from the MODEL U-SES study.

SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.

Many of the top stories in cardiology last week were from Healio’s live coverage of the Heart Failure Society of America’s Scientific Meeting. They included an interview with retired basketball star Shaq, who discusses how a new campaign intends to raise awareness of heart failure in blacks.

PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, provides a deep dive on the THEMIS and THEMIS-PCI trials presented at the European Society of Cardiology Congress.

Among a U.S. population of socioeconomically disadvantaged adults, a polypill-based strategy was associated with greater reductions in systolic BP and LDL compared with the usual care, according to findings published in The New England Journal of Medicine.

According to new data from the COMPASS trial, patients with systemic atherosclerosis assigned low-dose rivaroxaban plus aspirin had reduced risk for cardioembolic stroke and embolic stroke of undetermined origin compared with patients assigned aspirin alone.

If one CVD event was considered to be equivalent to one major bleed, 2.5% of women and 12.1% of men without CVD were likely to have a 5-year net benefit from an aspirin regimen, researchers reported in the Annals of Internal Medicine.

Taking aspirin for primary prevention of cardiovascular disease does not benefit older adults, according to findings from the ASPREE trial presented at the European Society of Cardiology Congress.

PARIS — When added to dual antiplatelet therapy, vorapaxar reduced platelet-mediated thrombogenicity without impacting clot kinetics in patients with and without diabetes, according to results from the OPTIMUS-5 study presented at the European Society of Cardiology Congress.

PARIS — In patients with atrial fibrillation who underwent PCI, an antithrombotic strategy of edoxaban plus a P2Y12 inhibitor was noninferior to a vitamin K antagonist-based triple regimen for bleeding, with no significant differences in ischemic events.